ALMOF.US Alphamab Oncology

Healthcare Biotechnology USA Stocks
1.02 USD
Close of Nov 14, 2026
1.02 1.06
Market cap
USD 986M
P/E
-
P/B
3.93x
ROE
-6.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is ALMOF.US undervalued?

Graham number

The Graham number of Alphamab Oncology cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Alphamab Oncology fundamental analysis

No fundamental analysis for Alphamab Oncology yet.

Alphamab Oncology stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Alphamab Oncology

Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal gr…

Full company profile